in , , ,

RFI – Improved Nerve Agent Treatment System

The U.S. Department of Defense (DoD) is conducting market research on manufacturing capabilities for the nerve agent antidote scopolamine for intramuscular administration.

The DoD’s Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office is responsible for the development, procurement, fielding, and sustaining of such medical treatments and prophylactic capabilities against chemical, radiological and nuclear threats. The current MCS-CDP portfolio includes nerve agent therapeutics, pretreatments and prophylactics at varying stages of clinical development, including FDA-approved drugs.

Currently, MCS-CDP is seeking capabilities from interested parties for the advanced development of the centrally-acting therapeutic scopolamine for intramuscular administration by military Service Members for use as an adjunct in conjunction with the pretreatment pyridostigmine bromide (PB) as well as the oxime/atropine and anticonvulsant therapies.

This Request for Information (RFI) seeks to identify existing sources for the active pharmaceutical ingredient scopolamine hydrobromide, and identify expertise for the development and/or manufacture of the drug product/ substance for FDA approval.

Further details are available via Solicitation Number: W911QY15S0007. Responses are due by April 8, 2015.

Ebola Vaccine Safety Trials

Positive Safety, Efficacy Results for VSV-EBOV Ebola Vaccine

Notable CBRN and Biodefense Contracts

Tetra Tech Awarded EPA National Homeland Security Research Contract